paclitaxel

Paclitaxel (Taxol) is a natural product and a microtubule polymer stabilizer. Paclitaxel has anti-tumor activity and causes cell death by inducing mitotic arrest, apoptosis, and cell autophagy.

7-O-(Amino-PEG4)-paclitaxel is a PEG-based linker used in PROTACs to connect two essential ligands, facilitating selective protein degradation through the ubiquitin-proteasome system in cells.

7-O-(Cbz-N-amido-PEG4)-paclitaxel is a PEG-based linker for PROTACs that connects two essential ligands, facilitating the formation of PROTAC molecules and enabling selective protein degradation through the ubiquitin-proteasome system within cells.

Paclitaxelsuccinate sulfo-NHS ester is a derivative of Paclitaxel and is utilized in cancer research.

Paclitaxel-MVCP ( MC-val-cit-pab-paclitaxel )is a paclitaxel derivative with an MC-Val-Cit-PAB linker, which can be used for the preparation of Paclitaxel conjugates for drug delivery and nanomedicine research.

Paclitaxel octadecanedioate is a prodrug form of paclitaxel that is comprised of paclitaxel conjugated to 1,18-octadecanedioic acid.1 Unlike paclitaxel, it does not promote tubulin polymerization in vitro when used at a concentration of 10 μM. A 5:1 mixture of paclitaxel octadecanedioate:human serum albumin (HSA) is cytotoxic to HT-1080, PANC-1, and HT-29 cells (IC50s = 12, 2.48, and 8.62 nM, respectively). This mixture reduces tumor growth and increases survival in an HT-1080 mouse xenograft model in a dose-dependent manner. |1. Callmann, C.E., Leguyader, C.L.M., Burton, S.T., et al. Antitumor activity of 1,18-octadecanedioic acid-paclitaxel complexed with human serum albumin. J. Am. Chem. Soc. 141(30), 11765-11769 (2019).

DHA-paclitaxel, also know as Taxoprexin, is prodrug comprised of the naturally occurring omega-3 fatty acid docosahexaenoic acid (DHA) covalently conjugated to the anti-microtubule agent paclitaxel. Because tumor cells take up DHA, DHA-paclitaxel is delivered directly to tumor tissue, where the paclitaxel moiety binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Paclitaxel also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). DHA-paclitaxel exhibits improved pharmacokinetic and toxicity profiles when compared to conventional paclitaxel and has demonstrated antineoplastic activity in animal models of cancer.

Paclitaxel Ceribate is a mitotic inhibitor used in cancer chemotherapy.

7-Troc-paclitaxel is a precursor of paclitaxel which has anti-tumor activity.

6α-hydroxy Paclitaxel (6α-OH-PTX) is a major metabolite of the anticancer compound paclitaxel and is partially cytotoxic.

7-Epi 10-desacetyl paclitaxel (10-Deacetyl-7-epipaclitaxel) shows IC50 values of 0.085 nM, against HeLa cells.

10-Deacetyl-7-xylosyl paclitaxel (7-Xylosyl-10-deacetyltaxol) is a Paclitaxel derivative with improved pharmacological features and higher water solubility,used in Chinese clinics to treat cancer.

Nab-Paclitaxel is an albumin-bound formulation of Paclitaxel nanoparticles known for its enhanced response rates and tolerability. Leveraging albumin as a delivery vehicle, this compound achieves a favorable pharmacokinetic (PK) profile [1] [2].

Paclitaxel-D5 (Standard) is a reference standard of Paclitaxel-D5 intended for quantitative analysis, quality control, and related biochemical research applications. Paclitaxel-d5 is the deuterated analog of Paclitaxel, a diterpenoid natural product originally isolated from Pacific yew bark. Paclitaxel-d5 maintains the parent compound’s ability to stabilize microtubules and induce mitotic arrest leading to apoptosis, and it is widely used as an internal standard in analytical assays and mechanistic drug studies.

NSC756093 potentially inhibits GBP1:PIM1 interaction. NSC756093 can be used in ovarian cancer studies.

1. 7-epi-Taxol (7-Epitaxol) is the major derivative of taxol found in cells and that its presence does not alter, in a major way, the overall biological activity of taxol.

10-Deacetyltaxol (10-DAT) is extracted from Taxus brevifolia barks.

LY3325656 is a GPR142 agonist suitable for clinical testing in human. LY3325656 demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. LY3325656 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.

Paclitaxel-2′-succinate NHS ester is a derivative of paclitaxel featuring a succinate linker with its carboxyl group activated as an NHS ester. The NHS ester moiety exhibits high reactivity towards amino or hydroxyl groups, facilitating its conjugation with various molecules (such as peptides, proteins, antibodies, enzymes, or polymers). This compound is utilized in the development of nanomedicines and cancer research.

Paclitaxel-bromothiophene is a semisynthetic taxane analogue of Paclitaxel. It exhibits potent antiproliferative activity against 4-T1 breast cancer cells, with an IC50 value of 15.18 nM. This compound also shows high binding affinity to C5aR1 (Kd= 19.4 μM). In 4-T1 breast cancer tumor-bearing mice, Paclitaxel-bromothiophene demonstrates excellent antitumor efficacy. It is applicable for breast cancer research.

Paclitaxel-maleimide is a form of Paclitaxel modified with a maleimide linker. It exhibits strong binding affinity to bovine serum albumin (BSA) and is applicable in tumor research.

Paclitaxel-13C is a compound with the C13-labeled isotope of Paclitaxel (TMSM-3141).

Paclitaxel EP Impurity P is a commonly used biochemical reagent that can serve as a biomaterial or organic compound for life science research.

3'-epi-Paclitaxel is a derivative of Paclitaxel, suitable for cancer research.